Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Inclusion Criteria:

• Age ≥18 years at diagnosis.

• Diagnosed with ATTRv-CM or ATTRwt-CM, mixed phenotype.

• Treated with tafamidis, as VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally oncedaily for ≥12 months or started on tafamidis 20 mg then switched to VYNDAMAX 61 mgfor ≥12 months

• Have had ≥1 pre- and ≥1 post-treatment neurologic assessments.

Exclusion Criteria:

• History of any organ transplant.

• Individuals who are non-ambulatory.

• Prior or current treatment with any disease-modifying therapy (investigational orapproved) alone or in combination, except tafamidis, as VYNDAQEL 80 mg [four 20-mgtafamidis meglumine capsules] orally once daily or VYNDAMAX 61 mg [one 61-mgtafamidis capsule] orally once daily.

• Peripheral neuropathy attributed to causes other than ATTR amyloidosis (eg, diabetesmellitus, B12 deficiency, hypothyroidism, shingles,Lyme disease, HIV infection,secondary to injury, chronic kidney disease).

• Patient's data fails to pass data quality checks.